Trial Profile

A Phase 1-2 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Dose-Expansion in Patients With Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABN 401 (Primary)
Indications Advanced breast cancer; Bone metastases; Carcinoma; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Sarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Abion

06 Jan 2025 Status changed from recruiting to completed.
16 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
16 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com